MicroRNA‑126 exerts antitumor functions in ovarian cancer by targeting EGFL7 and affecting epithelial‑to‑mesenchymal transition and ERK/MAPK signaling pathway Retraction in /10.3892/ol.2024.14548

Zhang,Yuhua; Qin,Xiaobo; Jiang,Juan; Zhao,Wenjie

doi:10.3892/ol.2020.11687

MicroRNA‑126 exerts antitumor functions in ovarian cancer by targeting EGFL7 and affecting epithelial‑to‑mesenchymal transition and ERK/MAPK signaling pathway

Retraction in: /10.3892/ol.2024.14548

Authors:
- Yuhua Zhang
- Xiaobo Qin
- Juan Jiang
- Wenjie Zhao
View Affiliations

Affiliations: Reproductive Medicine Centre, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Obstetrics and Gynecology, Zhangqiu District Maternal and Child Health Care Hospital, Jinan, Shandong 250200, P.R. China , Department of Nursing, The Third People's Hospital of Qingdao, Qingdao, Shandong 266041, P.R. China
Published online on: May 29, 2020 https://doi.org/10.3892/ol.2020.11687
Pages: 1327-1335
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC) is a common gynecological malignant carcinoma worldwide. Accumulating research has revealed that multiple microRNAs (miRNAs) are abnormally expressed at different levels in various malignancies, playing vital roles in tumorigenesis. This study investigated the regulatory functions and potential mechanism of miR‑126 in OC proliferation, invasion and migration. It was found that miR‑126 was prominently downregulated in OC. Moreover, the decrease of miR‑126 promoted the aggressive phenotypes and indicated poor prognosis of OC patients. Functional assays demonstrated that restoration of miR‑126 dramatically repressed OC cell proliferation, migration and invasion. Furthermore, luciferase reporter assay was conducted to verify putative binding sites of miR‑126 in the epidermal growth factor‑like domain 7 (EGFL7) 3' untranslated region (3'UTR), indicating that EGFL7 was a target gene of miR‑126 in OC cells. It was further discovered that miR‑126 exerts its function on regulating ERK/MAPK pathway and epithelial‑to‑mesenchymal transition (EMT) in OC cells. The above findings suggested that miR‑126 served as a cancer suppressor in OC, suggesting a promising application of miR‑126 in the clinical diagnosis and therapeutics of OC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Mathieu KB, Bedi DG, Thrower SL, Qayyum A and Bast RC Jr: Screening for ovarian cancer: Imaging challenges and opportunities for improvement. Ultrasound Obstet Gynecol. 51:293–303. 2018. View Article : Google Scholar : PubMed/NCBI
3	Marth C, Reimer D and Zeimet AG: Front-line therapy of advanced epithelial ovarian cancer: standard treatment. Annals of oncology. Ann Oncol. 28 (Suppl 8):viii36–viii39. 2017. View Article : Google Scholar
4	Falzone L, Salomone S and Libra M: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. 9:13002018. View Article : Google Scholar : PubMed/NCBI
5	Lowry KP and Lee SI: Imaging and screening of ovarian cancer. Radiol Clin North Am. 55:1251–1259. 2017. View Article : Google Scholar : PubMed/NCBI
6	Lew D, Sundaram V, Barrows BD, Lo SK and Gaddam S: Resolution of diffuse intrahepatic biliary strictures after chemotherapy for metastatic ovarian cancer. ACG Case Rep J. 4:e772017. View Article : Google Scholar : PubMed/NCBI
7	Kuehn BM: The hunt continues for early ovarian cancer clues. JAMA. 318:14–16. 2017. View Article : Google Scholar : PubMed/NCBI
8	Fang RH and Ji XB: Advances in the research of the relationship between miRNA-29c and cancer. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 32:312–317. 2018.(In Chinese). PubMed/NCBI
9	Gilot D and Galibert MD: miRNA displacement as a promising approach for cancer therapy. Mol Cell Oncol. 5:e14064322017. View Article : Google Scholar : PubMed/NCBI
10	Falzone L, Lupo G, La Rosa GRM, Crimi S, Anfuso CD, Salemi R, Rapisarda E, Libra M and Candido S: Identification of novel MicroRNAs and their diagnostic and prognostic significance in oral cancer. Cancers (Basel). 11:6102019. View Article : Google Scholar
11	Markou A, Zavridou M and Lianidou ES: miRNA-21 as a novel therapeutic target in lung cancer. Lung Cancer (Auckl). 7:19–27. 2016.PubMed/NCBI
12	Zheng R, Liu Y, Zhang X, Zhao P and Deng Q: miRNA-200c enhances radiosensitivity of esophageal cancer by cell cycle arrest and targeting P21. Biomed Pharmacother. 90:517–523. 2017. View Article : Google Scholar : PubMed/NCBI
13	Candido S, Lupo G, Pennisi M, Basile MS, Anfuso CD, Petralia MC, Gattuso G, Vivarelli S, Spandidos DA, Libra M, et al: The analysis of miRNA expression profiling datasets reveals inverse microRNA patterns in glioblastoma and Alzheimer's disease. Oncol Rep. 42:911–922. 2019.PubMed/NCBI
14	Hafsi S, Candido S, Maestro R, Falzone L, Soua Z, Bonavida B, Spandidos DA and Libra M: Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. Oncol Lett. 11:1021–1025. 2016. View Article : Google Scholar : PubMed/NCBI
15	Falzone L, Candido S, Salemi R, Basile MS, Scalisi A, McCubrey JA, Torino F, Signorelli SS, Montella M and Libra M: Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. Oncotarget. 7:72758–72766. 2016. View Article : Google Scholar : PubMed/NCBI
16	Yan L, Yao J and Qiu J: miRNA-495 suppresses proliferation and migration of colorectal cancer cells by targeting FAM83D. Biomed Pharmacother. 96:974–981. 2017. View Article : Google Scholar : PubMed/NCBI
17	Qi R, Wang DT, Xing LF and Wu ZJ: miRNA-21 promotes gastric cancer growth by adjusting prostaglandin E₂. Eur Rev Med Pharmacol Sci. 22:1929–1936. 2018.PubMed/NCBI
18	Cheng Y, Xiang G, Meng Y and Dong R: MiRNA-183-5p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting the PDCD4. Reprod Biol. 16:225–233. 2016. View Article : Google Scholar : PubMed/NCBI
19	Jia Z, Zhang Y, Xu Q, Guo W and Guo A: miR-126 suppresses epithelial-to-mesenchymal transition and metastasis by targeting PI3K/AKT/Snail signaling of lung cancer cells. Oncol Lett. 15:7369–7375. 2018.PubMed/NCBI
20	Zhao C, Li Y, Zhang M, Yang Y and Chang L: miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2. Hum Cell. 28:91–99. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, Zhou J, Hu J and Jiang B: Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep. 30:1976–1984. 2013. View Article : Google Scholar : PubMed/NCBI
22	Aceto N, Toner M, Maheswaran S and Haber DA: En route to metastasis: Circulating tumor cell clusters and epithelial-to-mesenchymal transition. Trends Cancer. 1:44–52. 2015. View Article : Google Scholar : PubMed/NCBI
23	Boreddy SR and Srivastava SK: Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model. Oncogene. 32:3980–3991. 2013. View Article : Google Scholar : PubMed/NCBI
24	Nichol D and Stuhlmann H: EGFL7: A unique angiogenic signaling factor in vascular development and disease. Blood. 119:1345–1352. 2012. View Article : Google Scholar : PubMed/NCBI
25	Pinte S and Soncin F: Egfl7 promotes tumor escape from immunity. OncoImmunology. 1:375–376. 2012. View Article : Google Scholar : PubMed/NCBI
26	Luo W, Shao C, Li N, Zhang F, Guo S, Duan Z, Zheng Q and He H: Expression of epidermal growth factor-like domain 7 correlates with clinicopathological features of osteosarcoma. Am J Transl Res. 7:1236–1245. 2015.PubMed/NCBI
27	Philippin-Lauridant G, Baranzelli MC, Samson C, Fournier C, Pinte S, Mattot V, Bonneterre J and Soncin F: Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer. Int J Oncol. 42:1367–1375. 2013. View Article : Google Scholar : PubMed/NCBI
28	Li Z, Ni CF, Zhou J, Shen XC, Yin Y, Du P and Yang C: Expression of epidermal growth factor-like domain 7 is increased by transcatheter arterial embolization of liver tumors. Asian Pac J Cancer Prev. 16:1191–1196. 2015. View Article : Google Scholar : PubMed/NCBI
29	Shen X, Han Y, Xue X, Li W, Guo X, Li P, Wang Y, Li D, Zhou J and Zhi Q: Epidermal growth factor-like domain 7 promotes cell invasion and angiogenesis in pancreatic carcinoma. Biomed Pharmacother. 77:167–175. 2016. View Article : Google Scholar : PubMed/NCBI
30	Wang XX, Yao XB, Qiang ZS and Zhu HL: Attenuation of EGFL7 inhibits human laryngocarcinoma cells growth and invasion. Int J Clin Exp Med. 8:3141–3155. 2015.PubMed/NCBI
31	Deng QJ, Xie LQ and Li H: Overexpressed MALAT1 promotes invasion and metastasis of gastric cancer cells via increasing EGFL7 expression. Life Sci. 157:38–44. 2016. View Article : Google Scholar : PubMed/NCBI
32	Oh J, Park SH, Lee TS, Oh HK, Choi JH and Choi YS: High expression of epidermal growth factor-like domain 7 is correlated with poor differentiation and poor prognosis in patients with epithelial ovarian cancer. J Gynecol Oncol. 25:334–341. 2014. View Article : Google Scholar : PubMed/NCBI
33	Liakouli V, Cipriani P, Di Benedetto P, Panzera N, Ruscitti P, Pantano I, Berardicurti O, Carubbi F, Esteves F, Mavria G, et al: Epidermal growth factor like-domain 7 and miR-126 are abnormally expressed in diffuse systemic sclerosis fibroblasts. Sci Rep. 9:45892019. View Article : Google Scholar : PubMed/NCBI
34	Landen CN Jr, Birrer MJ and Sood AK: Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 26:995–1005. 2008. View Article : Google Scholar : PubMed/NCBI
35	Fu Q, Chen Z, Gong X, Cai Y, Chen Y, Ma X, Zhu R and Jin J: β-Catenin expression is regulated by an IRES-dependent mechanism and stimulated by paclitaxel in human ovarian cancer cells. Biochem Biophys Res Commun. 461:21–27. 2015. View Article : Google Scholar : PubMed/NCBI
36	Polo A, Crispo A, Cerino P, Falzone L, Candido S, Giudice A, De Petro G, Ciliberto G, Montella M, Budillon A, et al: Environment and bladder cancer: Molecular analysis by interaction networks. Oncotarget. 8:65240–65252. 2017. View Article : Google Scholar : PubMed/NCBI
37	Falzone L, Scola L, Zanghì A, Biondi A, Di Cataldo A, Libra M and Candido S: Integrated analysis of colorectal cancer microRNA datasets: Identification of microRNAs associated with tumor development. Aging (Albany NY). 10:1000–1014. 2018. View Article : Google Scholar : PubMed/NCBI
38	Falzone L, Romano GL, Salemi R, Bucolo C, Tomasello B, Lupo G, Anfuso CD, Spandidos DA, Libra M and Candido S: Prognostic significance of deregulated microRNAs in uveal melanomas. Mol Med Rep. 19:2599–2610. 2019.PubMed/NCBI
39	Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W and Chen K: Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One. 8:e778532013. View Article : Google Scholar : PubMed/NCBI
40	Lv T, Song K, Zhang L, Li W, Chen Y, Diao Y, Yao Q and Liu P: miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1. Biochem Cell Biol. 96:663–671. 2018. View Article : Google Scholar : PubMed/NCBI
41	Zheng HB, Zheng XG and Liu BP: miRNA-101 inhibits ovarian cancer cells proliferation and invasion by down-regulating expression of SOCS-2. Int J Clin Exp Med. 8:20263–20270. 2015.PubMed/NCBI
42	Li J, Li Q, Huang H, Li Y, Li L, Hou W and You Z: Overexpression of miRNA-221 promotes cell proliferation by targeting the apoptotic protease activating factor-1 and indicates a poor prognosis in ovarian cancer. Int J Oncol. 50:1087–1096. 2017. View Article : Google Scholar
43	Huang W, Lin J and Zhang H: miR-126: A novel regulator in colon cancer. Biomed Rep. 4:131–134. 2016. View Article : Google Scholar : PubMed/NCBI
44	Jing BQ, Ou Y, Zhao L, Xie Q and Zhang YX: Experimental study on the prevention of liver cancer angiogenesis via miR-126. Eur Rev Med Pharmacol Sci. 21:5096–5100. 2017.PubMed/NCBI
45	Feng R, Beeharry MK, Lu S, Sah BK, Yuan F, Yan M, Liu B, Li C and Zhu Z: Down-regulated serum miR-126 is associated with aggressive progression and poor prognosis of gastric cancer. Cancer Biomark. 22:119–126. 2018. View Article : Google Scholar : PubMed/NCBI
46	Li Y, Li Y, Ge P and Ma C: MiR-126 regulates the ERK pathway via targeting KRAS to inhibit the glioma cell proliferation and invasion. Mol Neurobiol. 54:137–145. 2017. View Article : Google Scholar : PubMed/NCBI
47	Wen Q, Zhao J, Bai L, Wang T, Zhang H and Ma Q: miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6. Oncol Rep. 34:2202–2210. 2015. View Article : Google Scholar : PubMed/NCBI
48	Luo J, Zhu C, Wang H, Yu L and Zhou J: MicroRNA-126 affects ovarian cancer cell differentiation and invasion by modulating expression of vascular endothelial growth factor. Oncol Lett. 15:5803–5808. 2018.PubMed/NCBI
49	Fan C, Yang LY, Wu F, Tao YM, Liu LS, Zhang JF, He YN, Tang LL, Chen GD and Guo L: The expression of Egfl7 in human normal tissues and epithelial tumors. Int J Biol Markers. 28:71–83. 2013. View Article : Google Scholar : PubMed/NCBI